Complement in human disease: approved and up-and-coming therapeutics

EE West, T Woodruff, V Fremeaux-Bacchi, C Kemper - The Lancet, 2024 - thelancet.com
The complement system is recognised as a protector against blood-borne pathogens and a
controller of immune system and tissue homoeostasis. However, dysregulated complement …

Therapeutic targeting of the complement system: from rare diseases to pandemics

P Garred, AJ Tenner, TE Mollnes, FO Levy - Pharmacological reviews, 2021 - Elsevier
The complement system was discovered at the end of the 19th century as a heat-labile
plasma component that “complemented” the antibodies in killing microbes, hence the name …

Tipping the balance: intricate roles of the complement system in disease and therapy

RB Pouw, D Ricklin - Seminars in Immunopathology, 2021 - Springer
The ability of the complement system to rapidly and broadly react to microbial intruders,
apoptotic cells and other threats by inducing forceful elimination responses is indispensable …

Immunological basis of the endometriosis: the complement system as a potential therapeutic target

C Agostinis, A Balduit, A Mangogna, G Zito… - Frontiers in …, 2021 - frontiersin.org
Endometriosis (EM) is a chronic disease characterized by the presence and proliferation of
functional endometrial glands and stroma outside the uterine cavity. Ovaries and pelvic …

How we ('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future

AM Risitano, R Peffault de Latour - British Journal of …, 2022 - Wiley Online Library
Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by complement‐mediated
intravascular haemolysis, severe thrombophilia and bone marrow failure. While for patients …

Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond

E Gavriilaki, RP de Latour… - Blood, The Journal of the …, 2022 - ashpublications.org
Complement is an elaborate system of innate immunity. Genetic variants and autoantibodies
leading to excessive complement activation are implicated in a variety of human diseases …

Complementopathies and precision medicine

E Gavriilaki, RA Brodsky - The Journal of clinical …, 2020 - Am Soc Clin Investig
The renaissance of complement diagnostics and therapeutics has introduced precision
medicine into a widened field of complement-mediated diseases. In particular, complement …

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

P Scheinberg, DV Clé, JS Kim, E Nur… - American Journal of …, 2024 - Wiley Online Library
Crovalimab, a novel C5 inhibitor, allows for low‐volume, every‐4‐week, subcutaneous self‐
administration. COMMODORE 1 (NCT04432584) is a phase 3, global, randomized trial …

Molecular pharmacology in complement‐mediated hemolytic disorders

M Bortolotti, W Barcellini… - European Journal of …, 2023 - Wiley Online Library
In the last decade, a deeper understanding of the pathogenesis of complement mediated
hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin …

Complement inhibitors for kidney disease

B Wooden, B Tarragon… - Nephrology Dialysis …, 2023 - academic.oup.com
ABSTRACT A refined understanding of the role of complement in the pathogenesis of
glomerular and other kidney diseases has, over the past two decades, been matched by the …